Mirre de Noo appointed as non-executive director

by QuantuMDx Team May 26, 2021

NEWCASTLE UPON TYNE, UK, 26 May 2021. QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director.

Mirre has over 20 years of experience in healthcare, strategy and innovation. As a life sciences and healthcare executive she has a track record of introducing and integrating novel state-of-the-art medical technologies in hospitals and with healthcare providers.

Currently, Mirre is the Chief Executive Officer of Reggeborgh Medical, a privately owned Dutch investment company and a Consultant Surgeon at Xpert Clinics, a private specialist medical service provider with 30 locations across the Netherlands.

Mirre serves as a board member and advisor at several life sciences and healthcare companies including Prescan and Amphera. She was also a member of the supervisory board of the national cancer screening programme in the Netherlands before joining Reggeborgh in 2019. Mirre has a PhD from Leiden University and qualified as a surgical oncologist and gastro-intestinal surgeon in 2013.

Neil Butler, Chairman of QuantuMDx, said: “On behalf of the Board, I would like to welcome Mirre to QuantuMDx. Mirre’s clinical knowledge, expertise and understanding of the use of diagnostics will be invaluable as we prepare to commercially launch our rapid point of care molecular diagnostic system, Q-POC™, later this year.”

Dr. Mirre de Noo, Non-Executive Director of QuantuMDx, said: “I am thrilled to be taking on this role within such a dynamic and promising company in molecular diagnostics. The explosion of knowledge about the structure of DNA is revolutionising for diagnostics and the treatment of many diseases. QuantuMDx has developed a high quality differentiated PCR-platform technology, Q-POC™, which could offer a solution to many healthcare problems now, and in the future.”

About QuantuMDx:

QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need, for anyone, anywhere.

QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics.

Q-POC™ is a rapid, simple to use, portable, sample to answer PCR device and has been designed for use in a wide range of settings, such as hospitals, clinics, pharmacies, and workplace testing providing accurate PCR results at the Point of Need. Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. It tests multiple targets of the disease for a future proof COVID-19 testing solution at the Point of Need.

QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years.

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com.